Merck & Co. on Thursday reported quarterly profit and sales that beat estimates and raised its full-year forecasts on strong demand for top-selling cancer drug Keytruda, its Gardasil vaccine and COVID-19 antiviral pill molnupiravir.
The U.S. drugmaker’s shares rose 1.8 percent to $85.90 before the opening bell as revenue rose 50 percent to $15.9 billion, with most of the growth coming from sales of molnupiravir, which was approved in November.
